An Open-lable, Multicenter, Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for patients with Metastatic Recurrent and/or Unresectable Renall Cell Carcinoma "(EVERMORE).
2022-06-29
عنوان الدراسة
An Open-lable, Multicenter, Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for patients with Metastatic Recurrent and/or Unresectable Renall Cell Carcinoma "(EVERMORE).
داعم الدراسة
Novartis
دواء الدراسة
RAD001 (Everolimus)
رقم بروتوكول الدراسة
CRAD001LIC01
حالة الدراسة
Rejected
موقع الدراسة
KFSH & RC-R
مرحلة الدراسة
2
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.